Tom Crosby

Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial

John P. Neoptolemos, Daniel H. Palmer, Paula Ghaneh et al. · The Lancet · 2017 · 1.9K citations · Full text

Capecitabine compared with observation in resected biliary tract cancer (BILCAP): a randomised, controlled, multicentre, phase 3 study

John Primrose, Richard Fox, Daniel H. Palmer et al. · The Lancet Oncology · 2019 · 1.2K citations · Full text

Surgical Oncology, Gastrointestinal Oncology, Medicine +10

Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for patients with previously untreated advanced oesophagogastric cancer (REAL3): a randomised, open-label phase 3 trial

Ian Chau, David Cunningham, David González et al. · The Lancet Oncology · 2013 · 723 citations · Full text

Oncology, Open-label Phase 3, Cancer Management +7

Multidisciplinary team management is associated with improved outcomes after surgery for esophageal cancer

Michael Stephens, Wyn G. Lewis, A. Brewster et al. · Diseases of the Esophagus · 2006 · 268 citations · Full text

Patterns of Recurrence After Resection of Pancreatic Ductal Adenocarcinoma

Robert Jones, Eftychia‐Eirini Psarelli, Richard Jackson et al. · JAMA Surgery · 2019 · 256 citations · Full text